Eris Lifesciences Limited CC-Nov25.pdf · 2025-11-12
Hi. Good evening. My name is Madhav. I am from Fidelity International. Am I audible?
Sir, I wanted to understand on similar lines on the GLP-1 opportunity. I wanted to -- first question was, what do you think will determine right to win once the generic semaglutide products start coming in the market? Like, who do you think has best right to win in India? Is it going to be more distribution and doctor access? Is it going to be supply-chain? Or what will determine who kind of gets more market share versus the other? That was one part. And second thing I want to understand is, do you think this market will be more dominated by the larger players like yourself who have a good positioning in, let's say, with the specialty doctors? Like, will they have a better share or do you see a lot of smaller players also getting a good toehold in this market?